Joint motion, surgery type tied to knee replacement outcomes
A greater range of motion before surgery is associated with better post-surgical outcomes for people with hemophilia who undergo…
Articles by Steve Bryson, PhD
Delayed diagnosis common in AHA, affecting 1 in 3 patients: Study
A delayed diagnosis is common for people with acquired hemophilia A (AHA), according to a new study that found…
Prophylaxis tops on-demand hem A treatment in cost-effectiveness
Prophylactic replacement therapy to prevent bleeds was more cost-effective than on-demand treatment of active bleeds for children and adolescents in…
Hemophilia A gene therapy superior to FVIII replacement in Phase 3 trial
Note: This story was updated July 30, 2024, to clarify patients participating in AFFINE had moderately severe to severe…
TiumBio’s hemophilia bypassing agent shows extended half-life
TU7710, an experimental treatment for managing bleeds in people with hemophilia who have inhibitors, demonstrated an average half-life that…
Efanesoctocog alfa, now Altuvoct, approved for hemophilia A in EU
Efanesoctocog alfa, a long-lasting factor VIII (FVIII) replacement therapy, has now been approved in the European Union for…
Switching to Hemlibra can control bleeds better in young patients
In real-world settings, Hemlibra (emicizumab-KXWH) can safely control bleeds in children with hemophilia A better than previous treatment…
FDA approves updated Altuviiio label with full XTEND-Kids data
The U.S. Food and Drug Administration (FDA) has approved an update to the prescribing information for Altuviiio (efanesoctocog alfa),…
Preventive Hemlibra for hemophilia A infants favored by HTC directors
Nearly all medical directors at hemophilia treatment centers in the U.S. said they would consider starting preventive Hemlibra (emicizumab-KXWH)…
Hemlibra controls hemophilia A bleeds over nearly 5 years: Analysis
Hemlibra (emicizumab-KXWH) safely controlled bleeds among hemophilia A patients without inhibitors over nearly five years of preventive treatment,…